Ifoxetine

Ifoxetine is a serotonin norepinephrine dopamine reuptake inhibitor that was studied for its potential use in the treatment of depression but was never marketed.

History

Ifoxetine was developed by Hoechst AG, a German pharmaceutical company, in the 1970s and 1980s. It was one of the first triple reuptake inhibitors to be developed and studied. However, despite showing promise in early trials, it was never marketed due to concerns about its safety profile.

Pharmacology

Ifoxetine acts as a reuptake inhibitor for the neurotransmitters serotonin, norepinephrine, and dopamine. This means it increases the levels of these neurotransmitters in the brain by preventing their reabsorption into the pre-synaptic neuron. This is thought to help alleviate the symptoms of depression.

Clinical trials

In clinical trials, ifoxetine showed some efficacy in treating depression. However, it also showed a relatively high incidence of side effects, including nausea, insomnia, and anxiety. These side effects, combined with concerns about its safety profile, led to its development being discontinued.

See also

• List of investigational antidepressants
• Reuptake inhibitor

References

Ifoxetine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski